drugset / Trial / NCT01082367

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

NCT01082367

Phase 3 Completed 50 enrolled Novartis Pharmaceuticals
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study investigated the efficacy of inhaled TOBI treatment for early infections of P. aeruginosa in paediatric patients with cystic fibrosis.

Timeline

Start
2010-04
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Tobramycin Small molecule 300 mg Inhaled